Hepion Pharmaceuticals (HEPA, Financial) has signed a binding letter of intent with New Day Diagnostics LLC to acquire licenses for diagnostic tests targeting celiac disease, respiratory conditions, helicobacter pylori, and hepatocellular carcinoma. These tests, which already possess CE marks, can currently be marketed across Europe. The market potential for these diagnostics is substantial, with an addressable market size surpassing $15 billion.
The collaboration leverages New Day Diagnostics' existing distribution network in the European Union, enabling Hepion to potentially generate immediate revenues. John Brancaccio, Hepion's Executive Chairman and Interim CEO, highlighted the strategic value of these tests and expressed eagerness to capitalize on this opportunity alongside New Day Diagnostics.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Hepion Pharmaceuticals Inc (HEPA, Financial) is $30.00 with a high estimate of $30.00 and a low estimate of $30.00. The average target implies an upside of 9,162.12% from the current price of $0.32. More detailed estimate data can be found on the Hepion Pharmaceuticals Inc (HEPA) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Hepion Pharmaceuticals Inc's (HEPA, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
